The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Hormone Refractory Prostate Cancer (HRPCA)-Global Market Insights and Sales Trends 2025
Synopsis
Hormone Refractory Prostate Cancer (HRPCA) or Castrate-Resistant Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after having hormonal Therapy, is now under the spotlight in prostate cancer market. Due to the high unmet clinical need associated with limited survival periods, intensifying HRPCA prevalence and fast-emerging treatment modifications, the global HRPCA market is poised to witness an unprecedented growth.
The global Hormone Refractory Prostate Cancer (HRPCA) market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Hormone Refractory Prostate Cancer (HRPCA) in various end use industries. The expanding demands from the Hospitals, Ambulatory Surgical Centers, Specialty Clinics and Others, are propelling Hormone Refractory Prostate Cancer (HRPCA) market. Cytotoxic Agents, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Anti-Androgens segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hormone Refractory Prostate Cancer (HRPCA), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Hormone Refractory Prostate Cancer (HRPCA) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Hormone Refractory Prostate Cancer (HRPCA) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hormone Refractory Prostate Cancer (HRPCA) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Hormone Refractory Prostate Cancer (HRPCA) covered in this report include Astellas Inc, Sanofi S.A, Dendreon Corporation, Bayer AG and Johnson & Johnson, etc.
The global Hormone Refractory Prostate Cancer (HRPCA) market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Astellas Inc
Sanofi S.A
Dendreon Corporation, Bayer AG
Johnson & Johnson
Global Hormone Refractory Prostate Cancer (HRPCA) market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hormone Refractory Prostate Cancer (HRPCA) market, Segment by Type:
Cytotoxic Agents
Anti-Androgens
Vaccines
Radio-Pharmaceuticals
Global Hormone Refractory Prostate Cancer (HRPCA) market, by Application
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Hormone Refractory Prostate Cancer (HRPCA) companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Hormone Refractory Prostate Cancer (HRPCA) or Castrate-Resistant Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after having hormonal Therapy, is now under the spotlight in prostate cancer market. Due to the high unmet clinical need associated with limited survival periods, intensifying HRPCA prevalence and fast-emerging treatment modifications, the global HRPCA market is poised to witness an unprecedented growth.
The global Hormone Refractory Prostate Cancer (HRPCA) market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Hormone Refractory Prostate Cancer (HRPCA) in various end use industries. The expanding demands from the Hospitals, Ambulatory Surgical Centers, Specialty Clinics and Others, are propelling Hormone Refractory Prostate Cancer (HRPCA) market. Cytotoxic Agents, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Anti-Androgens segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hormone Refractory Prostate Cancer (HRPCA), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Hormone Refractory Prostate Cancer (HRPCA) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Hormone Refractory Prostate Cancer (HRPCA) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hormone Refractory Prostate Cancer (HRPCA) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Hormone Refractory Prostate Cancer (HRPCA) covered in this report include Astellas Inc, Sanofi S.A, Dendreon Corporation, Bayer AG and Johnson & Johnson, etc.
The global Hormone Refractory Prostate Cancer (HRPCA) market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Astellas Inc
Sanofi S.A
Dendreon Corporation, Bayer AG
Johnson & Johnson
Global Hormone Refractory Prostate Cancer (HRPCA) market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hormone Refractory Prostate Cancer (HRPCA) market, Segment by Type:
Cytotoxic Agents
Anti-Androgens
Vaccines
Radio-Pharmaceuticals
Global Hormone Refractory Prostate Cancer (HRPCA) market, by Application
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Hormone Refractory Prostate Cancer (HRPCA) companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Hormone Refractory Prostate Cancer (HRPCA)
1.1 Hormone Refractory Prostate Cancer (HRPCA) Market Overview
1.1.1 Hormone Refractory Prostate Cancer (HRPCA) Product Scope
1.1.2 Hormone Refractory Prostate Cancer (HRPCA) Market Status and Outlook
1.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2018-2029)
1.4 Global Hormone Refractory Prostate Cancer (HRPCA) Historic Market Size by Region (2018-2023)
1.5 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Hormone Refractory Prostate Cancer (HRPCA) Market Size (2018-2029)
1.6.1 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size (2018-2029)
1.6.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size (2018-2029)
1.6.3 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size (2018-2029)
1.6.4 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size (2018-2029)
1.6.5 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size (2018-2029)
2 Hormone Refractory Prostate Cancer (HRPCA) Market by Type
2.1 Introduction
2.1.1 Cytotoxic Agents
2.1.2 Anti-Androgens
2.1.3 Vaccines
2.1.4 Radio-Pharmaceuticals
2.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Hormone Refractory Prostate Cancer (HRPCA) Historic Market Size by Type (2018-2023)
2.2.2 Global Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Hormone Refractory Prostate Cancer (HRPCA) Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Hormone Refractory Prostate Cancer (HRPCA) Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue Breakdown by Type (2018-2029)
3 Hormone Refractory Prostate Cancer (HRPCA) Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Ambulatory Surgical Centers
3.1.3 Specialty Clinics
3.1.4 Others
3.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Hormone Refractory Prostate Cancer (HRPCA) Historic Market Size by Application (2018-2023)
3.2.2 Global Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Hormone Refractory Prostate Cancer (HRPCA) Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Hormone Refractory Prostate Cancer (HRPCA) Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue Breakdown by Application (2018-2029)
4 Hormone Refractory Prostate Cancer (HRPCA) Competition Analysis by Players
4.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Hormone Refractory Prostate Cancer (HRPCA) as of 2022)
4.3 Date of Key Players Enter into Hormone Refractory Prostate Cancer (HRPCA) Market
4.4 Global Top Players Hormone Refractory Prostate Cancer (HRPCA) Headquarters and Area Served
4.5 Key Players Hormone Refractory Prostate Cancer (HRPCA) Product Solution and Service
4.6 Competitive Status
4.6.1 Hormone Refractory Prostate Cancer (HRPCA) Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Astellas Inc
5.1.1 Astellas Inc Profile
5.1.2 Astellas Inc Main Business
5.1.3 Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Products, Services and Solutions
5.1.4 Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Revenue (US$ Million) & (2018-2023)
5.1.5 Astellas Inc Recent Developments
5.2 Sanofi S.A
5.2.1 Sanofi S.A Profile
5.2.2 Sanofi S.A Main Business
5.2.3 Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Products, Services and Solutions
5.2.4 Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Revenue (US$ Million) & (2018-2023)
5.2.5 Sanofi S.A Recent Developments
5.3 Dendreon Corporation, Bayer AG
5.3.1 Dendreon Corporation, Bayer AG Profile
5.3.2 Dendreon Corporation, Bayer AG Main Business
5.3.3 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Products, Services and Solutions
5.3.4 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Revenue (US$ Million) & (2018-2023)
5.3.5 Johnson & Johnson Recent Developments
5.4 Johnson & Johnson
5.4.1 Johnson & Johnson Profile
5.4.2 Johnson & Johnson Main Business
5.4.3 Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Products, Services and Solutions
5.4.4 Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Revenue (US$ Million) & (2018-2023)
5.4.5 Johnson & Johnson Recent Developments
6 North America
6.1 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Hormone Refractory Prostate Cancer (HRPCA) Market Dynamics
11.1 Hormone Refractory Prostate Cancer (HRPCA) Industry Trends
11.2 Hormone Refractory Prostate Cancer (HRPCA) Market Drivers
11.3 Hormone Refractory Prostate Cancer (HRPCA) Market Challenges
11.4 Hormone Refractory Prostate Cancer (HRPCA) Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
